Mice with human immune system components as in vivo models for infections with human pathogens

Immunology and Cell Biology

Volumn 89, Issue 3, 2011, Pages 408-416

  Rämer, Patrick C ^a   Chijioke, Obinna ^a   Meixlsperger, Sonja ^a   Leung, Carol S ^a   Münz, Christian ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

dengue virus; Epstein Barr virus; HIV; human vaccination; natural killer cells; T cells

Indexed keywords

DENDRITIC CELL VACCINE; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TETANUS TOXOID;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; BONE MARROW CELL; CELL COMPARTMENTALIZATION; CELL DIVISION; DENGUE; DENGUE VIRUS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IN VIVO STUDY; INFLUENZA; INNATE IMMUNITY; LEUKOCYTE; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; TETANUS; VACCINATION; VIRUS PATHOGENESIS;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; MICE; MODELS, ANIMAL; VACCINATION;

ANIMALIA; DENGUE VIRUS; HUMAN HERPESVIRUS 4; MUS;

EID: 79952814422     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.151     Document Type: Review

References (87)

1. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P et al. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420: 520-562. (Pubitemid 35477048)
2. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-2738. (Pubitemid 38263654)
3. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988; 335: 256-259.
4. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988; 241: 1632-1639.
5. null mice. Blood 2005; 106: 1565-1573. (Pubitemid 41208567)
6. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 104-107. (Pubitemid 38451466)
7. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006; 12: 1316-1322. (Pubitemid 44706935)
8. + cells. Blood 2003; 102: 127-135. (Pubitemid 36759645)
9. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206: 25-34.
10. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA et al. The abundant NK cells in human lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455-1462. (Pubitemid 38116788)
11. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186: 1129-1136. (Pubitemid 27441156)
12. Kwant-Mitchell A, Pek EA, Rosenthal KL, Ashkar AA. Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge. PLoS ONE 2009; 4: e8379.
13. Pek EA, Chan T, Reid S, Ashkar AA. Characterization and IL-15 dependenceof NKcells in humanized mice. Immunobiology 2011; 216: 218-224.
14. Chen Q, Khoury M, Chen J. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci USA 2009; 106: 21783-21788.
15. Strowig T, Chijioke O, Carrega P, Arrey F, Meixlsperger S, Ramer PC et al. Human NK cells of mice with reconstituted human immune system components require pre-activation to acquire functional competence. Blood 2010; 116: 4158-4167.
16. + T cell maintenance and a functional arrest of immature NK cells. J Immunol 2010; 185: 2710-2720.
17. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-induced human lymphocyte apoptosis and cytokine production in 'humanized' mice. J Leukoc Biol 2009; 86: 219-227.
18. /, and C.B-17-scid/bg immunodeficient mice. Hum Immunol 2009; 70: 790-802.
19. null mice. Hum Immunol 2010; 71: 551-559.
20. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F et al. Targeting the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008; 112: 1231-1239.
21. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-1260.
22. + dendritic cells. J Exp Med 2010; 207: 1261-1271.
23. + dendritic cells. J Exp Med 2010; 207: 1273-1281.
24. + dendritic cells. J Exp Med 2010; 207: 1283-1292.
25. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492. (Pubitemid 30646489)
26. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768. (Pubitemid 39331148)
27. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44. (Pubitemid 40299772)
28. Babcock JG, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000; 13: 497-506.
29. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 2004; 101: 239-244. (Pubitemid 38084234)
30. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessonsfrom Epstein-Barrvirus. Annu Rev Immunol 2007; 25: 587-617. (Pubitemid 46697918)
31. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000; 54: 19-48.
32. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991; 173: 147-158.
33. Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O'Reilly RJ. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoprolifera-tions in xenografted C.B-17 scid/scid mice. J Exp Med 1996; 183: 1215-1228.
34. + cells with Epstein-Barr virus. J Virol 2004; 78: 13891-13900. (Pubitemid 39612786)
35. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008; 198: 673-682.
36. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J et al. Primingof protectiveTcell responses against virus-induced tumors in mice with human immune system compo-nents. J Exp Med 2009; 206: 1423-1434.
37. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H et al. Tcell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis 2009; 200: 1611-1615.
38. null humanized mice. Proc Natl Acad Sci USA 2010; 107:13022-13027.
39. / mice as a model for Epstein-Barr virus infection. Am J Pathol 2008; 173: 1369-1378.
40. Li N, Thompson S, Schultz DC, Zhu W, Jiang H, Luo C et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS ONE 2010; 5: e 10126.
41. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. Embo J2000; 19: 3080-3089. (Pubitemid 30386778)
42. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: cluesto the pathogenesis of Burkitt's lymphoma. Oncogene 2008; 27: 421-433.
43. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Denguefever in humanized NOD/SCID mice. J Virol 2005; 79: 13797-13799.
44. Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 2009; 83: 8638-8645.
45. / (RAG-hu) mice. Virology 2007; 369: 143-152. (Pubitemid 350029864)
46. null mice. PLoS ONE2009; 4: e7251.
47. Van Duyne R, Pedati C, Guendel I, Carpio L, Kehn-Hall K, Saifuddin M et al. The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 2009; 6: 76.
48. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM. Infection of the SCID-hu mouse by HIV-1. Science 1988; 242: 1684-1686. (Pubitemid 19022172)
49. Stanley SK, McCune JM, Kaneshima H, Justement JS, Sullivan M, Boone E et al. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med 1993; 178: 1151-1163. (Pubitemid 23277349)
50. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, Chen IS et al. The SCID-hu mouse as a model for HIV-1 infection. Nature 1993; 363: 732-736. (Pubitemid 23227652)
51. Bonyhadi ML, Rabin L, Salimi S, Brown DA, Kosek J, McCune JM et al. HIV induces thymus depletion in vivo. Nature 1993; 363: 728-732. (Pubitemid 23227651)
52. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991; 251: 791-794. (Pubitemid 21926171)
53. Torbett BE, Picchio G, Mosier DE. hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol Rev 1991; 124: 139-164.
54. / mice. Proc Natl Acad Sci USA 2006; 103: 15951-15956. (Pubitemid 44657573)
55. / (RAG-hu) mice. Virology 2008; 373: 342-351.
56. null mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiencyvirustype 1 pathogenesis. J Virol 2007; 81: 13259-13264. (Pubitemid 350156965)
57. null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007; 109: 212-218. (Pubitemid 46070123)
58. Zhang L, Kovalev GI, Su L. HIV-1 infection and pathogenesis in a novel humanized mousemodel. Blood 2007; 109: 2978-2981. (Pubitemid 46482096)
59. / mice. J Virol 2007; 81: 2700-2712. (Pubitemid 46447035)
60. + T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007; 204: 705-714. (Pubitemid 46631601)
61. An DS, Poon B, Ho Tsong Fang R, Weijer K, Blom B, Spits H et al. Use of a novel chimeric mouse model with afunctionallyactivehuman immunesystem tostudy human immunodeficiencyvirustype 1 infection. Clin Vaccine Immunol 2007; 14: 391-396.
62. null mice infected with CCR5-tropic HIV-1. Vaccine 2010; 28 (Suppl 2): B32-B37.
63. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiencyvirus-infected humanized BLT mice. J Virol 2009; 83: 7305-7321.
64. null mice. Virology 2009; 394: 64-72.
65. / mice in vivo. Blood 2008; 112: 2858-2868.
66. + cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol 2010; 184: 7082-7091.
67. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5: e16.
68. + cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiencyvirus. J Virol 2008; 82: 12145-12153.
69. / (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 2010;397: 100-103.
70. Hofer U, Schlaepfer E, Baenziger S, Nischang M, Regenass S, Schwendener R et al. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog 2010; 6: e1000867.
71. Dittmer D, Stoddart C, Renne R, Linquist-Stepps V, Moreno ME, Bare C et al. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu Thy/Liv mice. J Exp Med 1999; 190: 1857-1868. (Pubitemid 30013851)
72. Gobbi A, Stoddart CA, Locatelli G, Santoro F, Bare C, Linquist-Stepps V et al. Coinfection of SCID-hu Thy/Liv mice with human herpesvirus 6 and human immuno-deficiencyvirustype 1. J Virol 2000; 74: 8726-8731. (Pubitemid 30666723)
73. Alfonzo M, Blanc D, Troadec C, Huerre M, Eliaszewicz M, Gonzalez G et al. Temporary restoration of immune response against Toxoplasma gondii in HIV-infected individuals after HAART, as studied in the hu-PBMC-SCID mouse model. Clin Exp Immunol 2002; 129:411-419. (Pubitemid 35024909)
74. Joseph A, Zheng JH, Chen K, Dutta M, Chen C, Stiegler G et al. Inhibition of in vivo HIV infection in humanized mice by genetherapy of human hematopoieticstem cellswith a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 2010; 84: 6645-6653.
75. Shimizu S, Hong P, Arumugam B, Pokomo L, Boyer J, Koizumi N et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010; 115: 1534-1544.
76. Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010; 18:370-376.
77. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134: 577-586.
78. + T-cell immu-nity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952-6958. (Pubitemid 35424086)
79. Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003; 101:3150-3156. (Pubitemid 36858009)
80. McMichael AJ. HIVvaccines. Annu Rev Immunol 2006; 24: 227-255.
81. Cohen J. AIDS research. Did Merck's failed HIVvaccine cause harm? Science 2007; 318:1048-1049. (Pubitemid 350134865)
82. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immuniza-tion with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3: 1389-1393. (Pubitemid 28011040)
83. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10: 431-438. (Pubitemid 29205479)
84. Okada M, Takemoto Y, Okuno Y, Hashimoto S, Yoshida S, Fukunaga Y et al. The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine 2005; 23: 2269-2272. (Pubitemid 40341465)
85. Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mousemodels. Vaccine 2007; 25: 3038-3040. (Pubitemid 46509464)
86. Camacho RE, Wnek R, Fischer P, Shah K, Zaller DM, Woods A et al. Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1*01 transgene: a model of SCID-hu mouse for vaccine development. Exp Hematol 2007; 35: 1219-1230. (Pubitemid 47088778)
87. + T-cell responses in humanized micevaccinated with influenza virusvaccines. Blood 2008; 112: 3671-3678.